

Case 8

Presented by
Dr Anita Sarma
Consultant Haematologist
Leeds Teaching Hospital NHS Trust.

Case

- 31 year old male investigated for incidental microcytic, hypochromic anaemia.
- Bilateral ankle pain, weight loss and night sweats
- PMH: Congenital talipes
- FHx: Treated Pulmonary Tuberculosis
- He previously declined investigation of his anaemia



Case

- BP 105/65 mmHg, HR 82bpm, temp 37.5°C,
- RR 18, Sats 98% on air
- HS: I+II with a mild ESM
- Icteric sclera
- Bibasal reduced air entry on chest auscultation
- Mild abdominal distension, palpable splenomegaly
- Bilateral ankle oedema
- Rt sided talipes

Investigations 1

On admission	
Hb	65g/L
Retic	178 x10 ⁹ /L
MCV	64fl
WBC	3.08 x10 ⁹ /L
Plts	246 x10 ⁹ /L
Neuts	2.62 x10 ⁹ /L
Lymphs	0.08 x10⁹/L
TBili	79 umol/L
ALP	648 U/L
Alb	20 g/L
ALT	100 U/L
CRP	138.8 mg/L
Ferritin	3421 ug/L

- CXR: Bibasal blunted costophrenic angles, rt peri-hilar patchy opacification
- Abdominal US: Small hypoechoic liver lesions, splenomegaly



Case

- Treated for Sepsis of unknown origin
- Continued deterioration with high swinging fevers $>39^{\circ}\text{C}$ and hypotension
- Increased peripheral oedema
- Transferred to ICU for inotropic support

Interactive question 1

Based on the information presented thus far what single screening investigation would you request next?

- a) CT Neck, Chest, Abdomen Pelvis
- b) Haemoglobin HPLC
- c) Autoantibody screen
- d) Septic screen/Virology
- e) Lactate Dehydrogenase
- f) Serum Lipid Profile
- g) Coagulation Screen

Investigations 2

After 1 week	
Hb	56g/L
WBC	3.79 x10 ⁹ /L
Plts	53x10⁹/L
Neuts	2.62 x10 ⁹ /L
TBili	116 umol/L
ALP	807 U/L
AST	302 U/L
ALT	76 U/L
LDH	678 U/L
Ferritin	25547 ug/L
Triglycerides	2.77 mmol/L
Clauss Fg	1.9g/L
EBV PCR	58011 U/mL

CT NCAP:

- Small bilateral pleural effusion
- 18cm splenomegaly
- Multiple splenic and hepatic hypoattenuating lesions
- Moderate vol. retroperitoneal and left pelvic lymphadenopathy
- Moderate vol. ascites




Interactive question 2

What test to identify the most likely cause for the clinical presentation would you request next?

- a) Soluble CD25
- b) Splenic biopsy
- c) Perforin and Granule Release Assay
- d) T cell subsets
- e) Bone marrow
- f) XIAP, SAP, CD27, CD70 expression/levels




Bone marrow aspirate x 20




- Oligoparticulate
- Clotted
- Cellular evidence of trilineage haematopoiesis
- Increased macrophage activity

Bone marrow aspirate x 40 - Haemophagocytosis



Bone marrow aspirate x 60



- Increased macrophage activity
- Haemophagocytosis



CD34+ = 0.73% of leucocytes of which 87% are CD117+ and <5% are CD19+. CD34-117+ = 5.8% of leucocytes.

CD64+ Monocytes = 7% of leucocytes of which 78% are CD14+.

Plasma cells = 0.65% of leucocytes with a normal phenotype.

CD3+ T-cells = 2.1% of leucocytes, of which 30% are CD4+ helper T-cells and 58% are CD8+ cytotoxic T-cells. NK-cells = 0.99% of leucocytes.


B-cells = 0.02% of leucocytes. Kappa:Lambda ratio = 1.8:1 (normal).

Interactive question 3

What is the suspected diagnosis?




- a) Intravascular Large B Cell Lymphoma with Haemophagocytic lymphohistiocytosis
- b) Adult-Onset Still's Disease
- c) X-Linked Lymphoproliferative Syndrome Type 1
- d) EBV- driven Haemophagocytic Lymphohistiocytosis
- e) Hodgkin Lymphoma with Haemophagocytic lymphohistiocytosis
- f) Metastatic Carcinoma
- g) Insufficient information to make a diagnosis

Trephine




- Hypercellular
- Distorted architecture
- Multifocal patchy infiltrate
- Numerous large atypical binucleate and multinucleate cells
- Reactive background with histiocytes and eosinophils
- Florid macrophage activity
- Interspersed preserved by reactive haematopoiesis

Trephine



Trephine








- Florid macrophage activity
- Numerous atypical multi-nucleate cells
- Reactive background
- Haemophagocytosis





Immunohistochemistry



- Numerous atypical multi-nucleate cells
- Reed-Sternberg phenotype with latent EBV expression

Interactive question 4

What is the final diagnosis?

- a) Intravascular Large B Cell Lymphoma with Haemophagocytic lymphohistiocytosis
- b) Adult-Onset Still's Disease
- c) X-Linked Lymphoproliferative Syndrome Type 1
- d) EBV- driven Haemophagocytic Lymphohistiocytosis
- e) Hodgkin Lymphoma with Haemophagocytic lymphohistiocytosis
- f) Metastatic Carcinoma

Diagnosis

f) EBV associated Hodgkin Lymphoma with
Haemophagocytic lymphohistiocytosis



Management and Outcome

- Initially managed for HLH with methylprednisolone and Anakinra
- Commenced ABVD switched to EBVD in view of low LVEF (<30%)
- Stormy course, multiple episodes of melaena, due pangastritis
- Good recovery, with normalisation of blood counts
- Discharged from hospital
- Patient declined further treatment as an outpatient and died shortly after




Summary

- 30 year old male presenting with non-specific and evolving signs and symptoms
- 3 Fs (Fever, Falling Counts, high Ferritin)
- High pretest probability of HLH
- High Hscore 203/337 (clinical, biological and morphological factors)
- Initial management for hyperinflammation
- Identification and treatment of underlying EBV associated Hodgkin Lymphoma
- High mortality with delayed identification and management

Take home message

- HLH severe uncontrolled hyperinflammatory syndrome
- Primary, pHLH, due to mutations affecting lymphocyte cytotoxicity and immune regulation (children and young adults)
- Secondary, sHLH triggered by infection, malignancy, auto-immune disorders
- High mortality, particularly those associated with haematological malignancy
- Prompt identification, based on a constellation of signs and symptoms and laboratory biomarkers
- Calculate Hscore in adults and the HLH-2004 score in children in those with high pretest probability
- Involve local/regional/national expert MDT to promptly identify and treat the underlying trigger
- Reduce morbidity and mortality.

GIRFT HLH Pathway Overview



<https://gettingitrightfirsttime.co.uk/wp-content/uploads/2024/07/HLH-Pathway-FINAL-V1-July-2024.html>

References

1. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues revised 5th Edition
2. GIRFT: Haemophagocytic Lymphohistiocytosis (HLH) Guidance on the diagnosis, treatment, management and governance. July 2024
3. Cox, Miriam F et al. Diagnosis and investigation of suspected haemophagocytic lymphohistiocytosis in adults: 2023 Hyperinflammation and HLH Across Speciality Collaboration (HiHASC) consensus guideline. *The Lancet Rheumatology*, Volume 6, Issue 1, e51 - e62
4. Knauf, J., Schenk, T., Ernst, T. *et al.* Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH): a scoping review unveils clinical and diagnostic patterns of a lymphoma subgroup with poor prognosis. *Leukemia* **38**, 235–249 (2024).
5. Ambrose Fistus V, Sharief M, Sarma A. Haemophagocytic lymphohistiocytosis (HLH) with concurrent Hodgkin's Disease. *BMJ Case Rep.* 2025 Mar 14;18(3):e261944.

Acknowledgments



Andy Rawstron
Ruth DeTute
Richard Leach
Sharon Barrans
Polly Talley
Jane Shingles
Rachel Bradbury
Anne Clarke
Phillip Thompson



Catherine Cargo
Cathy Burton
Alesia Khan
Roger Owen
Reuben Tooze
Hiba Ali



Mohiuddin Sharief
Vanessa Ambrose Fistus